Sichuan Clover Biopharmaceuticals

Clover Biopharmaceuticals is a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates for infectious diseases as well as cancer and autoimmune diseases. The company's proprietary Trimer-Tag technology platform allows for the production of trimeric fusion proteins that mimic the natural structure of viral and cellular proteins. Their lead product, SCB-2019 (CpG 1018/Alum), is a recombinant protein-based COVID-19 vaccine that has received Emergency Use Authorization in multiple countries and is part of the COVAX Facility. Clover is also advancing a pipeline of biosimilars and innovative biologics targeting large unmet medical needs in immunology and oncology.